This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Depression or Anxiety
and you are
between 18 and 80
years old
The phase for this study is not defined.
Show me locations

The purpose

The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) testing on clinical outcomes in a group of subjects exhibiting neuropsychiatric disorders, such as depression and anxiety, as compared to a group of subjects with the same attributes without the guidance of PGx testing for their treatment. This study will also evaluate whether pharmacogenetic (PGx) testing can reduce adverse drug events, hospitalization rates, hospital length of stay, emergency room visits, disability, death or other serious drug side effects.

Provided treatments

  • Genetic: IDgenetix Neuropsychiatric Test Panel
Tris trial is registered with FDA with number: NCT02411123. The sponsor of the trial is AltheaDx and it is looking for 220 volunteers for the current phase.
Official trial title:
Prospective Randomized Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders